Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.

[1]  M. Banerjee,et al.  Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Stalteri,et al.  Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[4]  J. Oesterling,et al.  Using prostate-specific antigen to eliminate the staging radionuclide bone scan. , 1997, The Urologic clinics of North America.

[5]  R. Bahnson,et al.  Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. , 1996, Clinical nuclear medicine.

[6]  T. Wheeler,et al.  Workgroup 2: Staging and reporting of prostate cancer‐‐Sampling of the radical prostatectomy specimen , 1996, Cancer.

[7]  N. Smith,et al.  The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. , 1995, The Journal of urology.

[8]  Oesterling Je,et al.  Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. , 1994 .

[9]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[10]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[11]  I. Eardley,et al.  Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. , 1992, British journal of urology.

[12]  M. Terris,et al.  Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  J. Oesterling,et al.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.

[14]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[15]  E. Messing,et al.  Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. , 1989, The Journal of urology.

[16]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[17]  H. Pendergrass,et al.  Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. , 1976, Radiology.

[18]  M. Potsaid,et al.  Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. , 1975, The American journal of roentgenology, radium therapy, and nuclear medicine.